338 related articles for article (PubMed ID: 28134800)
1. Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.
Kalina JL; Neilson DS; Comber AP; Rauw JM; Alexander AS; Vergidis J; Lum JJ
Cancers (Basel); 2017 Jan; 9(2):. PubMed ID: 28134800
[TBL] [Abstract][Full Text] [Related]
2. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.
Aragon-Ching JB; Williams KM; Gulley JL
Front Biosci; 2007 Sep; 12():4957-71. PubMed ID: 17569623
[TBL] [Abstract][Full Text] [Related]
3. The Response of Prostate Cancer to Androgen Deprivation and Irradiation Due to Immune Modulation.
Wu CT; Chen WC; Chen MF
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30587810
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
Chen RC; Rosenman JG; Hoffman LG; Chiu WK; Wang AZ; Pruthi RS; Wallen EM; Crane JM; Kim WY; Rathmell WK; Godley PA; Whang YE
BJU Int; 2012 Dec; 110(11 Pt B):E721-6. PubMed ID: 23016517
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.
Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD
Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831
[TBL] [Abstract][Full Text] [Related]
6. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study.
Dell'Oglio P; Abou-Haidar H; Leyh-Bannurah SR; Tian Z; Larcher A; Gandaglia G; Fossati N; Shariat SF; Capitanio U; Briganti A; Montorsi F; Graefen M; Saad F; Karakiewicz PI
Eur Urol; 2016 Sep; 70(3):429-35. PubMed ID: 26951945
[TBL] [Abstract][Full Text] [Related]
8. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy.
Siddiqui ZA; Krauss DJ
Transl Androl Urol; 2018 Jun; 7(3):378-389. PubMed ID: 30050798
[TBL] [Abstract][Full Text] [Related]
10. Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review.
Dal Pra A; Cury FL; Souhami L
Curr Oncol; 2010 Oct; 17(5):28-38. PubMed ID: 20975876
[TBL] [Abstract][Full Text] [Related]
11. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer: does sequencing matter?
Weller MA; Kupelian PA; Reddy CA; Stephans KL; Tendulkar RD
Clin Genitourin Cancer; 2015 Jun; 13(3):e183-9. PubMed ID: 25660127
[TBL] [Abstract][Full Text] [Related]
13. External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer.
Dell'Oglio P; Bandini M; Leyh-Bannurah SR; Tian Z; Trudeau V; Larcher A; Fossati N; Moschini M; Gandaglia G; Capitanio U; Briganti A; Graefen M; Montorsi F; Saad F; Karakiewicz PI
Urol Oncol; 2018 May; 36(5):239.e9-239.e15. PubMed ID: 29426698
[TBL] [Abstract][Full Text] [Related]
14. The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer.
Zhao S; Urdaneta AI; Anscher MS
Expert Rev Anticancer Ther; 2016 Sep; 16(9):929-42. PubMed ID: 27464256
[TBL] [Abstract][Full Text] [Related]
15. Age-dependent overall survival benefit of androgen deprivation therapy for metastatic prostate cancer.
Keating MJ; Giscombe L; Tannous T; Reddy N; Mukkamalla SKR; DeSouza A; Rathore R
J Oncol Pharm Pract; 2019 Dec; 25(8):1927-1932. PubMed ID: 30880568
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy as backbone therapy in the management of prostate cancer.
Merseburger AS; Alcaraz A; von Klot CA
Onco Targets Ther; 2016; 9():7263-7274. PubMed ID: 27942220
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.
Alberti C
G Chir; 2017; 37(5):225-235. PubMed ID: 28098061
[TBL] [Abstract][Full Text] [Related]
18. Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer.
Thomas HR; Chen MH; D'Amico AV; Bennett CL; Kattan MW; Sartor O; Stein K; Nguyen PL
Clin Genitourin Cancer; 2018 Aug; 16(4):313-317. PubMed ID: 29866496
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
